2023 Cancer Reporting Requirements (Archived)
The NAACCR VERSION 23 standards will affect data collection in Florida starting with cases diagnosed in 2023 forward. Please be sure to read the 2023 FCDS DAM to familiarize yourself with the new requirements. Be sure you have all the necessary updated manuals on your desktop when abstracting a case.
New Data Items for FCDS:
Data Item # 1291- RX Summ- Surg Prim Site 2023
Codes starting with A indicate no significant change to the surgery code.
Codes starting with B indicate changes to the surgery code(s).
FCDS has incorporated these new surgery codes in the 2023 DAM, Appendix F.
Data Item # 3960- Histologic Subtype T
This data item is only for the Appendix Schema 09190.
Revised Data Item for FCDS:
Data Item # 1290- RX Summ-Surg Prim Site is now RX Summ--Surg Prim Site 03-2022.
Only the name changed. This data item will still collect the surgery codes for cases with a diagnosis date of on or before 2022.
Data Item # 3956- p16
This is an existing SSDI for the cervix V9 (schema id 09520).
It is being added to the Anus V9 (schema id 09210).
Data Items No Longer Required for FCDS:
Date flag data items retired in 2023.
They will no longer be transmitted in the NAACCR record.
All edit checks with date flags have either been deleted or modified.
Coding Clarifications
Starting in 2023 Cases diagnosed with pilocytic astrocytoma/juvenile pilocytic astrocytoma 9421 are to be reported with behavior /1. Cases diagnosed prior to 1/1/2023 are coded 9421/3.
Starting with 2023 cases, Code 9421/3 will be valid for diagnoses of high-grade astrocytoma with piloid features (HFAP).
The following histologies have been approved for use with primaries of the cervix C53 for diagnosis year 2021 and forward. Previously, registrars were instructed to use these histologies for cervical primaries starting with cases diagnosed in 2022 forward.
8085 Squamous cell carcinoma, HPV-associated C51.9; C52.9; C53.X_
8086 Squamous cell carcinoma, HPV-independent C51.9; C52.9; C53.X_
8483 Adenocarcinoma, HPV-associated
8484 Adenocarcinoma, HPV-independent, NOS
8482 Adenocarcinoma, HPV-independent, gastric type
8310 Adenocarcinoma, HPV-independent, clear cell type
9110 Adenocarcinoma, HPV-independent, mesonephric type C53.X; C56.9
Solid Tumor Rules- 2023 Site Specific Updates
CNS- Malignant and Non-Malignant
New instructions were added for Pilocytic Astrocytoma tumors
Breast
Clarifications to Rule M10 and the applicable histology rules for coding lobular and ductal tumors were added; “Assign behavior code /3 even when an in-situ histology is mixed with an invasive. This aligns with ICDO-3.2 and was vetted with specialty matter experts.”
Prostate
New Rule M4- Abstract multiple primaries when the patient has a subsequent small cell carcinoma 8041 of the prostate more than 1 year following a diagnosis of acinar adenocarcinoma and/or subtype/variant of acinar adenocarcinoma of prostate (Table 3).
Head & Neck
Table 9 was redesigned; New timing rule: Abstract multiple primaries when the patient has a subsequent tumor after being clinically disease-free for greater than five years after the original diagnosis or last recurrence.
C754 and C755 added to the H&N module.
Other Sites
This chapter was completely revised. Same format, histology coding requirements and timing instructions as the current solid tumor rules for the site-specific modules.
New Rule M8- Abstract multiple primaries when separate/non-contiguous tumors are anaplastic carcinoma and any other histologies in the thyroid. Note: This rule does not apply to multiple tumors that are anaplastic carcinoma and undifferentiated carcinoma.
Can’t find what you are looking for? Click on the tags below to see related articles: